The 48 references in paper S. Avdeev N., С. Авдеев Н. (2014) “Значение мукоактивных препаратов в терапии хронической обструктивной болезни легких // Role of mucoactive drugs in treatment of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2011:i:4:p:118-124

1
Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2010 report is available on www.goldcopd.com
(check this in PDF content)
2
Tashkin D.P., Celli B., Senn S. et al.for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.
(check this in PDF content)
3
Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care 2007; 52: 1176–1193.
(check this in PDF content)
4
Openshaw P.J., Turner)Warwick M.Observations on sputum production in patients with variable airflow obstruction; implications for the diagnosis of asthma and chronic bronchitis. Respir. Med. 1989; 83: 25–31.
(check this in PDF content)
5
Turner)Warwick M., Openshaw P.Sputum in asthma. Postgrad. Med. J. 1987; 63 (Suppl. 1): 79–82.
(check this in PDF content)
6
Rogers D.F., Barnes P.J.Treatment of airway mucus hypersecretion. Ann. Med. 2006; 38: 116–125.
(check this in PDF content)
7
Speizer F.E., Fay M.E., Dockery D.W. et al. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am. Rev. Respir. Dis. 1989; 140 (Suppl. 3): S49–S55.
(check this in PDF content)
8
Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir. J. 1995; 8: 1333–1338.
(check this in PDF content)
9
Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. 1996; 153: 1530–1535.
(check this in PDF content)
10
Burgel P.)R., Nesme)Meyer P., Chanez P. et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975–982.
(check this in PDF content)
11
Marco R., Accordini S., Cerveri I. et al.Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am. J. Respir. Crit. Care Med. 2007; 175: 32–39.
(check this in PDF content)
12
Kohansal R., Martinez)Camblor P., Agusti A. et al. The natural history of chronic air flow obstruction revisited: an analysis of the Framingham offspring cohort. Am. J. Respir. Crit. Care Med. 2009; 180: 3–10.
(check this in PDF content)
13
Hogg J.C., Chu F.S., Tan W.C. et al.Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airways pathology. Am. J. Respir. Crit. Care Med. 2007; 176: 454–459.
(check this in PDF content)
14
Vestbo J. Epidemiological studies in mucus hypersecretion. In: Chadwick D.J., Goode J.A., eds. Novartis foundation symposium 248: mucus hypersecration in respiratory disease. Malden: Wiley; 2002. 277–282.
(check this in PDF content)
15
Burgel P.R., Nadel J.A. Epidermal growth factor receptormediated innate immune responses and their roles in airway diseases. Eur. Respir. J. 2008; 32: 1068–1081.
(check this in PDF content)
16
Randell S.H., Boucher R.C.Effective mucus clearance is essential for respiratory health. Am. J. Respir. Cell. Mol. Biol. 2006; 35: 20–28. Рис. 6. Амброксол и риск развития обострений у больных ХОБЛ [48]
(check this in PDF content)
17
Innes A.L., Carrington S.D., Thornton D.J. et al. Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am. J. Respir. Crit. Care Med. 2009; 180: 203–210.
(check this in PDF content)
18
Lethem M.I., James S.L., Marriott C., Burke J.F.The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur. Respir. J. 1990; 3: 19–23.
(check this in PDF content)
19
Tomkiewicz R.P., Kishioka C., Freeman J., Rubin B.K.DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G.L., Priel Z., Roth Y. et al., eds. Cilia, mucus, and mucociliary interactions. New York: Dekker; 1998. 333–341.
(check this in PDF content)
20
Shah S.A., Santago P., Rubin B.K. Quantification of biopolymer filament structure. Ultramicroscopy 2005; 104: 244–254.
(check this in PDF content)
21
Hogg J.C., Chu F., Utokaparch S. et al. The nature of smallairway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645–2653.
(check this in PDF content)
22
James A.L., Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur. Respir. J. 2007; 30: 134–155.
(check this in PDF content)
23
Macklem P.T., Proctor D.F., Hogg J.C.The stability of peripheral airways. Respir. Physiol. 1970; 8: 191–203.
(check this in PDF content)
24
Vliet A., O'Neill C.A., Cross C.E. et al.Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. Am. J. Physiol. 1999; 276: L289– L296.
(check this in PDF content)
25
Rahman I., Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 2006; 28: 219–242.
(check this in PDF content)
26
Ricevuti G., Mazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax 1988; 43: 585–590.
(check this in PDF content)
27
Moldeus P., Cotgreave I.A., Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50: 31–42.
(check this in PDF content)
28
Gillissen A. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir. Med. 1998; 92: 609–623.
(check this in PDF content)
29
Curran D.R., Cohn L. Advances in mucous cell metaplasia: a plug for mucus as a therapeutic focus in chronic airway disease. Am. J. Respir. Cell. Mol. Biol. 2010; 42: 268–275.
(check this in PDF content)
30
Woodruff P.G., Wolff M., Hohlfeld J.M. et al.Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181: 438–445.
(check this in PDF content)
31
Singer M., Martin L.D., Vargaftig B.B. et al.A MARCKSrelated peptide blocks mucus hypersecretion in a mouse model of asthma. Nature Med. 2004; 10: 193–196.
(check this in PDF content)
32
Zheng J.P., Kang J., Huang S.G. et al.Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 2008; 371: 2013–2018.
(check this in PDF content)
33
Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br. Med. J. 2001; 322: 1271–1274.
(check this in PDF content)
34
Poole P., Black P.N.Mucolytic agents for chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 19 (3): JulCD001287.
(check this in PDF content)
35
Rensch H., Seefeld H.Surfatant-mucus interaction. In: Robertson B., Van Golde L.M., Batenburg J.J., eds. Pulmonary surfactant. Amsterdam: Elsevier; 1984. 203–214.
(check this in PDF content)
36
Haagsman H.P., Van Golde L.M.Lung surfactant and pulmonary toxicytology. Lung 1985; 163: 275–303.
(check this in PDF content)
37
Jarstrand C. Role of surfactant in the pulmonary defence system. In: Robertson B., Van Golde L.M., Batenburg J.J., eds. Pulmonary surfactant. Amsterdam: Elsevier; 1984. 188–201.
(check this in PDF content)
38
Disse B.G. The pharmacology of ambroxol-review and new results. Eur. J. Respir. Dis. 1987; Suppl.153: 255–262.
(check this in PDF content)
39
Beeh K.M., Beier J., Esperester A., Paul L.D.Antiinflammatory properties of ambroxol. Eur. J. Med. Res. 2008; 13: 557–562.
(check this in PDF content)
40
Фархутдинов У.Р., Петряков В.В., Фархутдинов Ш.У. Эффективность амброксола (Лазолвана®) у больных хронической обструктивной болезнью легких. Пульмонология 2009; 1: 73–76.
(check this in PDF content)
41
Фархутдинов У.Р., Фархутдинов Р.Р., Петряков В.В. и др. Влияние муколитической терапии на продукцию активных форм кислорода в крови у больных с обострением хронической обструктивной болезни легких. Тер. арх. 2010; 3: 29–32.
(check this in PDF content)
42
Ottonello L., Arduino N., Bertolotto M. et al. In vitro inhibition of human neutrophil histotoxicity by ambroxol: Evidence for a multistep mechanism. Br. J. Pharmacol. 2003; 140: 736–742.
(check this in PDF content)
43
Li F., Wang W., Hu L. et al.Effect of ambroxol on pneumonia caused by pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model. Chemotherapy 2011; 57: 173–180.
(check this in PDF content)
44
Lu Q., Yu J., Yang X. et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int. J. Antimicrob. Agents. 2010; 36: 211–215.
(check this in PDF content)
45
Xia D.)H., Xi L., Xv C. et al.The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor β1and tumor necrosis factor α. Med. Oncol. 2010; 27: 697–701.
(check this in PDF content)
46
Olivieri D., Zavattini G., Tomasini G. et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration 1987; 51 (Suppl. 1): 42–51.
(check this in PDF content)
47
Puscinska E., Radwan L., Zielinski J. Effect of intravenous ambroxol hydrochloride on lung function and exercise capacity in patients with severe chronic obstructive pulmonary disease. Pneumonol. Alergol. Pol. 1994; 62: 246–249.
(check this in PDF content)
48
Malerba M., Ponticiello A., Radaeli A. et al. Effect of twelvemonths therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm. Pharmacol. Ther. 2004; 17: 27–34.
(check this in PDF content)